Table 1.

Pathology of EAE Mice Treated with IGF-1 during the Acute Phase

Period of treatment	Day sampled	Treatment/control	Inflammation	Demyelination	Remyelination	Wallerian degeneration
3–17 dpt	10	Tx	2.4 ± 0.5	1.3 ± 1.1	0	0
		Con	3.7 ± 0.7	2.7 ± 0.7	0	0
	14	Tx	2.7 ± 0.7	1.5 ± 1.2	1.4 ± 0.5	1.0 ± 0
		Con	2.9 ± 0.6	2.5 ± 1.1	1.7 ± 0.5	2.2 ± 0.4
	54	Tx	1.1 ± 1.0	0.8 ± 1.0	1.0 ± 0	0
		Con	2.7 ± 0.5	2 ± 0.8	2.0 ± 0	1.5 ± 0.5
3–17 dpt	29	Tx	1.8 ± 0.6	1.0 ± 0.8	1.5 ± 0.5	1.8 ± 0.4
		Con	2 ± 0.5	1.1 ± 0.8	1.8 ± 0.4	2.2 ± 0.9
	71	Tx	2.1 ± 0.6	1.9 ± 1.0	1.2 ± 0.2	1.5 ± 0.5
		Con	1.8 ± 0.7	1.3 ± 0.7	0	0
3–17 dpt	11	Tx	0	0	0	0
		Con	2.8 ± 1.7	2.7 ± 2.6	1.0 ± 0	2.0 ± 0
	11 mo	Tx	1.8 ± 0.3	1.7 ± 0.9	1.0 ± 0	0
		Con	1.6 ± 0.5	1.6 ± 0.7	1.2 ± 0.4	0